Patent US7662829B2 successfully refreshed from Google Patents.
← Back to Patent Explorer
US7662829B2 Active / In Force US ⏱️ 1.3 years remaining

Methods, compositions, and kits for organ protection during systemic anticancer therapy

Assignee: Asymmetric Therapeutics LLC
•
Filing: 2008-03-05
•
Granted: 2010-02-16
•
Expires: 2028-03-05
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Methods, compositions, and kits are presented for local tissue protection during systemic administration of anticancer therapeutic agents.

Inventors

  • 👤 John P. Ford

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-29 16:05
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/495; A61K31/505; A61K31/513; A61K31/335; A61K31/337; A61K31/555; A61K31/70; A61K31/7028; A61K31/7034; A61K31/704; A61K31/7042; A61K31/7052; A61K31/706; A61K31/7064; A61K31/7068; A61K31/7072; A61P; A61P17/00; A61P39/00; A61P43/00

Claims Analysis

Total Claims: 18
Claim 1
Independent Claim 88 words
A method of protecting skin surfaces of a human in need thereof from the undesirable side-effects of one or more systemically distributed anticancer therapeutic agents or metabolites comprised of 5-fluorouracil or a prodrug thereof without abrogating the clinical efficacy of said systemically distributed anticancer therapeutic agent or metabolite, comprising: administering a formulation comprising uracil to the skin surfaces in an amount that is effective to protect against the undesirable side-effects of one or more systemically distributed anticancer therapeutic agents or metabolites comprised of 5-fluorouracil or a prodrug thereof.
Claim 2
Independent Claim 88 words
A method of protecting skin surfaces of a human in need thereof from the undesirable side-effects of one or more systemically distributed anticancer therapeutic agents or metabolites comprised of 5-fluorouracil or a prodrug thereof without abrogating the clinical efficacy of said systemically distributed anticancer therapeutic agent or metabolite, comprising: administering a formulation comprising uracil to the skin surfaces in an amount that is effective to protect against the undesirable side-effects of one or more systemically distributed anticancer therapeutic agents or metabolites comprised of 5-fluorouracil or a prodrug thereof.
Claim 3
Dependent Claim 14 words
The method of claim 1 , wherein the skin surface is the palmar surface.
Claim 4
Dependent Claim 14 words
The method of claim 1 , wherein the skin surface is the plantar surface.
Claim 5
Dependent Claim 50 words
The method of claim 1 , wherein the concentration of uracil in the formulation that is effective to protect against the effects of one or more systemically distributed anticancer therapeutic agents or metabolites comprised of 5-fluorouracil or a prodrug thereof is about 0.01 wt. % to about 20 wt. %.
Claim 6
Dependent Claim 49 words
The method of claim 1 , wherein the concentration of uracil in the formulation that is effective to protect against the effects of one or more systemically distributed anticancer therapeutic agents or metabolites comprised of 5-fluorouracil or a prodrug thereof is about 0.01 wt.% to about 10 wt. %.
Claim 7
Dependent Claim 50 words
The method of claim 1 , wherein the concentration of uracil in the formulation that is effective to protect against the effects of one or more systemically distributed anticancer therapeutic agents or metabolites comprised of 5-fluorouracil or a prodrug thereof is about 0.01 wt. % to about 5 wt. %.
Claim 8
Dependent Claim 45 words
The method of claim 1 , wherein the concentration of uracil in the formulation that is effective to protect against the effects of one or more systemically distributed anticancer therapeutic agents or metabolites comprised of 5-fluorouracil or a prodrug thereof is about 0.01 wt. %.
Claim 9
Dependent Claim 40 words
The method of claim 1 , wherein the concentration of uracil effective to protect against the effects of one or more systemically distributed anticancer therapeutic agents or metabolites comprised of 5-fluorouracil or a prodrug thereof is about 0.1 wt. %.
Claim 10
Dependent Claim 40 words
The method of claim 1 , wherein the concentration of uracil effective to protect against the effects of one or more systemically distributed anticancer therapeutic agents or metabolites comprised of 5-fluorouracil or a prodrug thereof is about 1 wt. %.
Claim 11
Independent Claim 92 words
A method of protecting palmar and plantar surfaces of a human in need thereof from the undesirable side-effects of one or more systemically distributed anticancer therapeutic agents or metabolites comprised of 5-fluorouracil or a prodrug thereof without abrogating the clinical efficacy of said systemically distributed anticancer therapeutic agent or metabolite, comprising: administering a formulation comprising uracil to the palmar and plantar surfaces in an amount that is effective to protect against the undesirable side-effects of one or more systemically distributed anticancer therapeutic agents or metabolites comprised of 5-fluorouracil or a prodrug thereof.
Claim 12
Independent Claim 92 words
A method of protecting palmar and plantar surfaces of a human in need thereof from the undesirable side-effects of one or more systemically distributed anticancer therapeutic agents or metabolites comprised of 5-fluorouracil or a prodrug thereof without abrogating the clinical efficacy of said systemically distributed anticancer therapeutic agent or metabolite, comprising: administering a formulation comprising uracil to the palmar and plantar surfaces in an amount that is effective to protect against the undesirable side-effects of one or more systemically distributed anticancer therapeutic agents or metabolites comprised of 5-fluorouracil or a prodrug thereof.
Claim 13
Dependent Claim 50 words
The method of claim 10 , wherein the concentration of uracil in the formulation that is effective to protect against the effects of one or more systemically distributed anticancer therapeutic agents or metabolites comprised of 5-fluorouracil or a prodrug thereof is about 0.01 wt. % to about 20 wt. %.
Claim 14
Dependent Claim 50 words
The method of claim 10 , wherein the concentration of uracil in the formulation that is effective to protect against the effects of one or more systemically distributed anticancer therapeutic agents or metabolites comprised of 5-fluorouracil or a prodrug thereof is about 0.01 wt. % to about 10 wt. %.
Claim 15
Dependent Claim 50 words
The method of claim 10 , wherein the concentration of uracil in the formulation that is effective to protect against the effects of one or more systemically distributed anticancer therapeutic agents or metabolites comprised of 5-fluorouracil or a prodrug thereof is about 0.01 wt. % to about 5 wt. %.
Claim 16
Dependent Claim 45 words
The method of claim 10 , wherein the concentration of uracil in the formulation that is effective to protect against the effects of one or more systemically distributed anticancer therapeutic agents or metabolites comprised of 5-fluorouracil or a prodrug thereof is about 0.01 wt. %.
Claim 17
Dependent Claim 45 words
The method of claim 10 , wherein the concentration of uracil in the formulation that is effective to protect against the effects of one or more systemically distributed anticancer therapeutic agents or metabolites comprised of 5-fluorouracil or a prodrug thereof is about 0.1 wt. %.
Claim 18
Dependent Claim 45 words
The method of claim 10 , wherein the concentration of uracil in the formulation that is effective to protect against the effects of one or more systemically distributed anticancer therapeutic agents or metabolites comprised of 5-fluorouracil or a prodrug thereof is about 1 wt. %.

References Cited (Backward Citations)

US5326764A Cited
US6979688B2 Cited
US6995165B2 Cited
US7368456B2 Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 2013-02-15 2013-08-17 2014-02-16 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2017-02-15 2017-08-17 2018-02-16 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2021-02-15 2021-08-17 2022-02-16 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag